Journey Medical Corporation (DERM)
| Market Cap | 136.65M -20.0% |
| Revenue (ttm) | 61.86M +10.2% |
| Net Income | -11.43M |
| EPS | -0.47 |
| Shares Out | 27.33M |
| PE Ratio | n/a |
| Forward PE | 68.97 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 149,429 |
| Open | 5.20 |
| Previous Close | 5.21 |
| Day's Range | 4.99 - 5.22 |
| 52-Week Range | 4.31 - 9.56 |
| Beta | 1.04 |
| Analysts | Strong Buy |
| Price Target | 12.67 (+153.4%) |
| Earnings Date | May 13, 2026 |
About DERM
Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company’s marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to se... [Read more]
Financial Performance
In 2025, Journey Medical's revenue was $61.86 million, an increase of 10.20% compared to the previous year's $56.13 million. Losses were -$11.43 million, -22.09% less than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for DERM stock is "Strong Buy." The 12-month stock price target is $12.67, which is an increase of 153.40% from the latest price.
News
Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026
Company to host conference call to discuss financial results and provide a corporate update on May 13, 2026 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a c...
Journey Medical secures contract with third major GPO for Emrosi
Journey Medical (DERM) announced that approximately 85% of all commercial lives in the United States now have access to Emrosi after contracting with the third major group purchasing organization, GPO...
Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™
Payer access for Emrosi™ expanded from approximately 100 million commercial lives to over 150 million commercial lives as of April 1, 2026 Payer access for Emrosi™ expanded from approximately 100 mill...
Journey Medical Corporation Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Journey Medical Corporation (NASDAQ: DERM). The investigation focuses on ...
Journey Medical price target raised to $12 from $11 at B. Riley
B. Riley raised the firm’s price target on Journey Medical (DERM) to $12 from $11 and keeps a Buy rating on the shares. Journey Medical delivered strong Q4 execution, with
Journey Medical reports FY25 EPS (47c) vs. (72c) last year
Reports FY25 revenue $61.9M, consensus $64.7M. Claude Maraoui, CEO, said, “We delivered a year of meaningful commercial progress, highlighted by the successful launch and rapid uptake of Emrosi(TM), w...
Journey Medical Earnings Call Transcript: Q4 2025
EMROSI's launch drove 11% revenue growth and improved margins in 2025, with strong prescription uptake and refill rates. Adjusted EBITDA turned positive, and expanding payer coverage is expected to further boost profitability and sales in 2026.
Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights
Total revenues were $61.9 million in FY2025 compared to $56.1 million in FY2024 Emrosi ™ generated net revenues of $14.7 million during the full-year period after its launch in early April 2025 Appro...
Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026
Company to host conference call to discuss financial results and provide a corporate update on March 25, 2026 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a...
Journey Medical management to meet virtually with Lake Street
Virtual Meeting to be held on February 26 hosted by Lake Street. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’
Journey Medical files $150M mixed securities shelf
16:45 EST Journey Medical (DERM) files $150M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks
Journey Medical announces results from Phase 1 trial of DFD-29
Journey Medical (DERM) announced that results from the Phase 1 clinical trial assessing the impact of low-dose oral minocycline, DFD-29, on skin, gastrointestinal and vaginal microflora in healthy adu...
Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology
Clinical trial achieved all three primary objectives with no significant safety issues being reported Results indicate that Emrosi can be safely used for up to 16 weeks with no detectable impact on sk...
Journey Medical price target raised to $16 from $10 at Alliance Global
Alliance Global raised the firm’s price target on Journey Medical (DERM) to $16 from $10 and keeps a Buy rating on the shares post the Q3 report. The firm cites
Journey Medical Earnings Call Transcript: Q3 2025
Q3 2025 saw 21% revenue growth, led by Emrosi's strong launch and rapid prescriber adoption. Gross margin improved sequentially, adjusted EBITDA turned positive, and the company expects sustainable EBITDA positivity in Q4 as payer coverage for Emrosi expands.
Journey Medical reports Q3 EPS (9c), consensus (4c)
Reports Q3 revenue $17.63M, consensus $18.85M. Claude Maraoui, Journey Medical’s (DERM) co-founder, president and CEO, said, “Our third quarter 2025 results reflect continued strong execution and acce...
Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
Third quarter 2025 net revenues were $17.6 million Emrosi™ total prescriptions increased 146% over the second quarter of 2025 Emrosi net revenues were $4.9 million Company to hold conference call toda...
Fourteen new option listings on November 12th
New option listings for November 12th include Direxion Daily AMD Bear 1X Shares (AMDD), Beta Bionics Inc (BBNX), Sprott Junior Copper Miners ETF (COPJ), Journey Medical Corp (DERM), Fidelity Magellan
Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025
Company to host conference call to discuss financial results and provide a corporate update on November 12, 2025 at 4:30 p.m. ET Company to host conference call to discuss financial results and provid...
Journey Medical presented efficacy data from two studies on Emrosi
Journey Medical (DERM) Corporation presented efficacy data from a pooled analysis of the two Phase 3 multicenter, randomized, double-blind, parallel-group, active-comparator and placebo-controlled cli...
Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference
FDA-approved Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) is available in the United States for the treatment of inflammatory ...
Journey Medical Corporation to Participate in October 2025 Investor Conferences
SCOTTSDALE, Ariz., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on sel...
Journey Medical Corporation to Participate in September 2025 Investor Conferences
SCOTTSDALE, Ariz., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on se...
Journey Medical initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Brandon Folkes initiated coverage of Journey Medical (DERM) with a Buy rating and $13 price target The firm believes the company’s Emrosi has demonstrated clinical superiority ...
Journey Medical Transcript: Emerging Growth Conference 85
A dermatology-focused pharmaceutical firm is experiencing rapid growth following the launch of Emrosi, a new oral therapy for rosacea that has shown superior efficacy and safety compared to the market leader. Prescription growth, payer access, and out-licensing deals are driving the company toward profitability in 2025.